This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pritchett, E. L. C. Search for Related Content PubMed PubMed Citation Articles by Pritchett, E. L. C.

Antiarrhythmic effects of azimilide in atrial fibrillation: efficacy and dose-response

Edward L. C. Pritchett, MD^a, Richard L. Page, MD, FACC^*, Stuart J. Connolly, MD, FACC, Stephen R. Marcello, MD, FACC, Daniel J. Schnell, PhD, William E. Wilkinson, PhD the Azimilide Supraventricular Arrhythmia Program 3 (SVA-3) Investigators

^a Department of Medicine, Divisions of Cardiology and Clinical Pharmacology, Duke University Medical Center, Durham, North Carolina, USA
^* Department of Medicine, Cardiovascular Division, University of Texas Southwestern Medical Center, Parkland Memorial Hospital, Dallas, Texas, USA
Department of Medicine, McMaster University, Hamilton, Ontario, Canada
Procter and Gamble Pharmaceuticals, Cincinnati, Ohio, USA
Department of Community and Family Medicine, Division of Biometry, Duke University Medical Center, Durham, North Carolina, USA

View larger version (17K): [in a new window]   Figure 1 Primary efficacy analysis. Time to symptomatic arrhythmia recurrence was significantly longer in the combined azimilide 100 mg QD and 125 mg QD dose group compared with the placebo group (chi-square 7.96, p = 0.005). QD = daily.

View larger version (16K): [in a new window]   Figure 2 Efficacy in subgroups. None of the subgroups demonstrated efficacy that was significantly different from the overall primary efficacy analysis. CHF = congestive heart failure; HD = heart disease; SHD = structural heart disease.

View larger version (23K): [in a new window]   Figure 3 Efficacy in individual doses compared with placebo. Time to first symptomatic arrhythmia recurrence increased across doses as the dose changed from placebo to 50 mg QD, 100 mg QD and 125 mg QD. CHF = congestive heart failure; QD = daily.